Bausch + Lomb to Detail Pipeline with Investor Webinar
Event summary
- Bausch + Lomb will host an R&D “Teach-in” webinar on March 23, 2026, at 1:30 p.m. ET.
- The webinar will focus on two glaucoma assets: BL1107 (medication) and ELIOS™ (minimally invasive surgery approach).
- ELIOS™ is already commercialized in Europe and slated for a U.S. launch in 2H 2026.
- Key executives including CEO Brent Saunders and R&D Chief Yehia Hashad will participate.
- The webinar is part of Wells Fargo’s Innovation Spotlight series.
The big picture
Bausch + Lomb’s webinar signals a renewed emphasis on showcasing its R&D pipeline following the November 2025 unveiling. The company is attempting to build investor confidence in its innovation engine, which is crucial for justifying its valuation and navigating a competitive landscape in the eye health market. The inclusion of senior leadership underscores the strategic importance of these pipeline assets to the company’s future growth.
What we're watching
- Regulatory Approval
- The success of ELIOS™ hinges on a timely and favorable U.S. regulatory review, given the existing European commercialization and the stated launch timeline.
- Clinical Adoption
- How quickly physicians adopt ELIOS™ will determine its market penetration and impact Bausch + Lomb’s revenue projections, particularly given its implant-free approach.
- Pipeline Risk
- The focus on BL1107, a first-in-class glaucoma medication, highlights the inherent risk associated with novel therapies and the potential for clinical trial setbacks.
Related topics